Antibiotic Resistance Market - By Disease, By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel - Global Forecast, 2026 - 2035

Antibiotic Resistance Market Size

The global antibiotic resistance market was valued at USD 9.9 billion in 2025. The market is expected to grow from USD 10.5 billion in 2026 to USD 18.7 billion in 2035, at a CAGR of 6.7% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is growing at a rapid pace due to the growing global crisis of antimicrobial resistance (AMR). The growing need for new treatment options in the wake of rising cases of multi-drug-resistant infections has made the market a pressing concern for the pharmaceutical industry, governments, and healthcare professionals across the world. The misuse of antibiotics, the growing number of hospital-acquired infections, and the development of resistant pathogens have all contributed to the growing need for new antibiotics, rapid diagnostics, and new treatments.

The growing number of older people increased surgical rates, and the prevalence of chronic diseases have all contributed to the risk of infection, making antibiotic resistance a pressing concern for patient safety and healthcare costs. Governments and global health authorities are enforcing tough stewardship programs and encouraging research and development through regulatory and funding programs. The growing awareness among healthcare professionals and patients is also contributing to the growth of the market. The market is at the forefront of innovation in the global healthcare industry in the fight against AMR. The major companies operating in the market are Pfizer, Merck & Co, Bayer AG, and AbbVie.
 

The antibiotic resistance market is witnessing sharp growth, expanding from USD 8.4 billion in 2022 to USD 9.4 billion in 2024. The development of the market is directly related to the increasing global threat of antimicrobial resistance (AMR) and the need for effective treatment options. This problem is being fueled by the increasing number of multidrug-resistant infections, which are threatening conventional treatments and driving up healthcare costs. According to WHO, antibiotic resistance is a problem that is most prominent in the South-East Asian and Eastern Mediterranean Regions, where 1 in 3 reported infections are resistant.
 

The market refers to the segment of the healthcare industry that focuses on the development, production, and use of antibiotics and alternative treatments to combat infections caused by antibiotic-resistant pathogens. This market includes the novel antibiotics and therapeutic solutions aimed at addressing the growing threat of resistance, which occurs when bacteria evolve to survive exposure to drugs that once killed them or inhibited their growth.

Antibiotic Resistance Market Trends

• In the market, a paradigm shift is being witnessed due to the integration of global health efforts, innovation in drug development technology, and changes in medical practices.
   
• Antimicrobial stewardship programs launched by governments and organizations are providing a strong foundation for market development. For example, WHO’s Global Action Plan on Antimicrobial Resistance and national plans emphasize responsible use of antibiotics, infection control, and early detection, which are driving the development of new drugs and new diagnostics.
   
• With this development, the rising incidence of multidrug-resistant infections is leading to a shift in the treatment landscape. The healthcare industry is increasingly seeking effective and cost-effective solutions to manage serious infections, reduce hospital stay times, and enhance outcomes, thus driving the development of new antibiotics and new treatments.
   
• Innovation in drug development and diagnostics technology is also happening at a breakneck speed. Organizations are leveraging AI platforms, rapid molecular diagnostics, and microbiome technologies to develop targeted therapies. For example, next-generation sequencing and point-of-care diagnostics enable rapid detection of resistant bacteria, thus enabling precision medicine and preventing the overuse of antibiotics.
   

Antibiotic Resistance Market Analysis

The market by disease is categorized into complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), bloodstream infection (BSI), acute bacterial skin and skin-structure infection (ABSSSI), community-acquired bacterial pneumonia (CABP), and hospital-acquired bacterial pneumonia (HABP). The complicated urinary tract infections (cUTI) segment held a significant market share of 30.2% in 2025. The segment is expected to reach USD 5.9 billion by 2035, growing with a CAGR of 7% during the forecast period. On the other hand, bloodstream infection (BSI) segment is expected to grow with fastest CAGR of 7.5%.
 

• In the antibiotic resistance market, the cUTI segment holds a significant share due to its high prevalence and clinical complexity. Patients with underlying conditions such as diabetes and kidney disease are more susceptible to cUTIs, increasing the demand for advanced antibiotic therapies.
   
• Clinical guidelines and research are shaping treatment strategies for cUTIs. Earlier IDSA guidelines focused on uncomplicated UTIs, but recent randomized controlled trials have evaluated new antimicrobials for cUTIs in both women and men, reflecting the growing importance of this segment. Women have a lifetime risk of 53% for UTIs, while men have a notable 14% risk, making this a widespread concern.
   
• The severity and complications associated with cUTIs drive the need for broad-spectrum antibiotics. These infections often involve multidrug-resistant pathogens, requiring therapies that can target a wide range of bacteria and reduce hospital stays and morbidity.
   
• Innovation in antibiotic development is a critical growth driver for this segment. Pharmaceutical companies are focusing on next-generation antibiotics and combination therapies to address resistance challenges. For example, new drugs approved for cUTI treatment are designed to combat resistant strains and improve patient outcomes, highlighting the segment’s role in advancing antimicrobial strategies.
   

Based on pathogen, the antibiotic resistance market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, Baumannii, S. pneumoniae, and H. influenzae. The E. coli segment accounted for 23.4% share in 2025 and is anticipated to witness significant growth during the forecast period.
 

• The Escherichia coli (E. coli) segment represents a critical area within the market due to its ability to cause severe infections and foodborne illnesses. E. coli infections can lead to symptoms such as stomach cramps, bloody diarrhea, and vomiting, typically appearing 3–4 days after exposure. In severe cases, complications such as kidney failure can occur, significantly increasing healthcare costs and patient risk.
   
• Recent outbreaks highlight the public health impact of E. coli. For instance, the E. coli O157 outbreak linked to romaine lettuce sickened 89 people across 15 states, resulting in 36 hospitalizations, 7 cases of kidney failure, and 1 death. Similarly, an outbreak associated with contaminated onions caused 104 illnesses, 34 hospitalizations, and 1 death. These incidents underscore the urgent need for effective antibiotic therapies and preventive measures.
   
• The growing prevalence of drug-resistant E. coli strains further complicates treatment, driving demand for broad-spectrum antibiotics and innovative solutions. Pharmaceutical companies are focusing on next-generation antibiotics and rapid diagnostics to address these challenges, making the E. coli segment a key contributor to market growth.
   

Based on drug class, the antibiotic resistance market is classified into oxazolidinones, cephalosporin, lipoglycopeptides, combination therapies, tetracyclines, and other drug classes. The oxazolidinones segment held largest share of 24.7% in 2025 and is expected to grow at CAGR of 7.2% over the coming years.
 

• Oxazolidinones, particularly Linezolid, are highly effective against Gram-positive bacteria, including strains resistant to multiple other antibiotic classes. These drugs exhibit strong activity against both aerobic and anaerobic Gram-positive organisms, making them critical in treating severe infections caused by resistant pathogens.
   
• The unique mode of action of oxazolidinones contributes to their growing adoption. They are bacteriostatic antibiotics, meaning they inhibit bacterial growth rather than killing bacteria directly, which helps prevent bacterial proliferation and reduces the risk of resistance development.
   
• Innovation and clinical demand are driving growth in this segment. With the rising prevalence of multidrug-resistant Gram-positive infections, oxazolidinones have become a cornerstone in hospital-based treatments and complex infection management. Their proven efficacy and inclusion in treatment guidelines further strengthen their market position.
   

Based on the mechanism of action, the antibiotic resistance market is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, and other mechanism of actions. Cell wall synthesis inhibitors segment held largest share of 37.2% in 2025 and is expected to grow at CAGR of 6.9% over the coming years.
 

• Cell wall synthesis inhibitors represent a crucial category in the antibiotic market. Drugs such as penicillin and cephalosporins act by targeting bacterial cell wall construction, specifically by disrupting peptidoglycan synthesis, which provides bacterial cells with structural integrity.
   
• By binding to enzymes such as penicillin-binding proteins (PBPs), these drugs prevent the cross-linking of peptidoglycan strands, weakening the cell wall and causing bacterial lysis. This selective mechanism makes these antibiotics highly effective against a wide array of bacterial infections, notably those caused by Gram-positive bacteria.
   
• In addition to beta-lactams, other cell wall inhibitors, such as glycopeptides, are instrumental in treating resistant strains such as MRSA, although their usage is generally reserved for more severe infections due to potential side effects.
   
• These advancements highlight the ongoing need for new, robust options in the market to maintain the clinical utility of this critical antibiotic class.
   

Based on the distribution channel, the antibiotic resistance market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2025, the hospital pharmacies segment accounted for market share of 50.3%.
 

• Retail pharmacies represent a critical distribution channel in the global market, primarily because they serve as an accessible point of care for patients requiring antibiotic therapies. For many individuals, retail pharmacies often act as the first touchpoint for obtaining prescribed antibiotics, making them an indispensable source for timely treatment and medication adherence.
   
• Retail pharmacies are preferred due to their convenience and immediate availability. Patients can quickly access antibiotics from nearby retail outlets, ensuring prompt initiation of therapy without delays associated with hospital visits or procurement challenges.
   
• As the global burden of antibiotic-resistant infections continues to rise, retail pharmacies will remain a vital distribution channel. Their integration into community healthcare pathways, coupled with the ability to provide patient education on proper antibiotic use and resistance prevention, further strengthens their role in combating antibiotic resistance.
   

North America Antibiotic Resistance Market
 

• North America remains a leading region in the global market, driven by its high burden of antimicrobial-resistant infections and strong healthcare infrastructure.
   
• According to the Global Research on Antimicrobial Resistance (GRAM) Project, bacterial AMR was linked to approximately 569,000 deaths across 35 countries in the Americas in 2023, accounting for 11.5% of global AMR fatalities. This underscores the growing healthcare crisis across the region.
   
• In Canada alone, AMR has been a persistent threat, with over 3,000 lives lost annually since 1990. In 2021, there were an estimated 2,840 deaths attributable to AMR and 13,300 deaths associated with AMR, with some of the most deadly pathogen-drug combinations including Staphylococcus aureus resistant to fluoroquinolones and methicillin, and Pseudomonas aeruginosa resistant to carbapenems.
   
• The AMR burden across North America has prompted federal and local governments to enhance funding for R&D in drug-resistant bacterial infection treatments. This growth trajectory is expected to continue as national action plans and insurance support expand, presenting significant opportunities for companies developing novel antibiotics and AMR-targeted therapies.
   

The U.S. antibiotic resistance market was valued at USD 3.1 billion and USD 3.3 billion in 2022 and 2023, respectively. The market size reached USD 3.7 billion in 2025, growing from USD 3.5 billion in 2024.
 

• The U.S. represents one of the most advanced and mature markets for combating antibiotic resistance globally, supported by a robust healthcare infrastructure, strong surveillance systems, and significant investments in antimicrobial stewardship programs.
   
• The country faces a substantial burden of antimicrobial-resistant infections, which continues to drive demand for innovative therapies and rapid diagnostics. According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, resulting in over 35,000 deaths.
   
• A major epidemiological factor shaping market growth is the rising prevalence of multidrug-resistant pathogens, including Staphylococcus aureus resistant to methicillin and fluoroquinolones, and Pseudomonas aeruginosa resistant to carbapenems. This growing threat reinforces the need for novel antibiotics, rapid point-of-care testing, and personalized treatment approaches.
   
• The U.S. market is characterized by advanced digital connectivity, with resistance monitoring tools integrated into EHRs and national surveillance systems. Combined with robust regulatory frameworks, policies, and government-led initiatives, these factors reinforce the country’s leadership in antibiotic resistance management and innovation.
   

Europe Antibiotic Resistance Market

Europe market accounted for USD 2.6 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe plays a critical role in the global market, driven by its robust healthcare infrastructure, comprehensive surveillance systems, and strong policy frameworks aimed at combating antimicrobial resistance (AMR).
   
• The region’s coordinated efforts under EU-level strategies, such as the European One Health Action Plan against AMR, have fostered significant progress in monitoring, prevention, and control of resistant infections across hospitals and community settings.
   
• Declining incidence rates of key resistant pathogens underscore the effectiveness of these initiatives. For instance, in 2023, the estimated EU incidence of meticillin resistant Staphylococcus aureus (MRSA) bloodstream infections was 4.64 per 100,000 population, marking a 17.6% reduction compared to the 2019 baseline year and already surpassing the 2030 target of 4.79 per 100,000.
   
• Similarly, the incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections stood at 10.35 per 100,000 population, reflecting ongoing challenges but also highlighting the impact of strengthened infection control and antimicrobial stewardship programs.
   
• Looking ahead, Europe is expected to remain a major contributor to the market, supported by sustained policy efforts, strong frameworks for novel treatments, and collaborative research programs aimed at developing next-generation antimicrobials.
   

Germany dominates the Europe antibiotic resistance market, showcasing strong growth potential.
 

• Germany represents a key segment of the European market, supported by its advanced healthcare infrastructure, strong national surveillance systems, and commitment to implementing EU-level strategies against antimicrobial resistance (AMR). The country’s well-established statutory health insurance system and emphasis on infection prevention have created a favorable environment for AMR control initiatives.
   
• The burden of AMR remains significant. In 2021, Germany recorded an estimated 8,000 deaths attributable to AMR and 40,900 deaths associated with AMR. The largest number of AMR-associated deaths occurred among individuals aged 70 years and older, reflecting the vulnerability of aging populations to resistant infections.
   
• Among the most deadly pathogen-drug combinations in Germany were: Staphylococcus aureus resistant to methicillin, Escherichia coli resistant to aminopenicillin and Pseudomonas aeruginosa resistant to carbapenems.
   
• These pathogens pose a critical challenge for healthcare providers, driving demand for novel antibiotics, rapid diagnostics, and advanced infection control solutions.
   
• As Germany continues to prioritize AMR mitigation through integrated strategies and collaborative research, the market is expected to expand steadily, supported by sustained efforts to reduce resistance rates, improve patient outcomes, and strengthen healthcare resilience.
   

Asia Pacific Antibiotic Resistance Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the analysis timeframe.
 

• The Asia Pacific region is emerging as one of the most critical markets in the global fight against antimicrobial resistance (AMR), driven by its vast population, high disease burden, and systemic challenges in healthcare delivery. Home to 53% of the world’s population, including over 600 million children, the region faces unique vulnerabilities that accelerate the spread of multidrug-resistant pathogens.
   
• Key factors fueling AMR prevalence include overcrowded healthcare facilities, excessive and poorly targeted antibiotic use, and insufficient infection prevention and control (IPC) resources. These structural gaps create an environment conducive to rapid transmission of resistant organisms, particularly in low-resource settings.
   
• Antibiotic overuse in children is a major concern across Asia Pacific, as access to microbiological diagnostics or even basic pathology tests remains limited. This diagnostic gap often leads to empirical and inappropriate antibiotic prescribing, further exacerbating resistance trends.
   
• Market growth is supported by increasing awareness, government-led AMR action plans, and international collaborations aimed at strengthening surveillance and stewardship programs. Investments in rapid diagnostics, infection control technologies, and novel antibiotic development are gaining momentum, particularly in countries such as India, China, and Southeast Asian nations where resistance rates are among the highest globally.
   
• As healthcare systems evolve and regional strategies intensify, Asia Pacific is expected to play a pivotal role in shaping the global market, offering significant opportunities for innovation in diagnostics, therapeutics, and digital health solutions to curb the AMR threat.
   

China antibiotic resistance market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China is a cornerstone of the market, driven by its vast population, high healthcare demand, and strategic national initiatives to curb antimicrobial resistance (AMR). The country’s multi-sectoral approach, backed by strong government commitment, is reshaping AMR management across hospitals and community settings.
   
• China’s policy framework is a major growth driver. In 2016, the government launched the One Health National Action Plan to Contain Antimicrobial Resistance (2016–2020), involving 14 ministries to ensure a coordinated response across human health, animal health, and environmental sectors. This comprehensive strategy underscores China’s leadership in addressing AMR at scale.
   
• Significant progress has been made in reducing antimicrobial use. According to WHO, the average rate of antimicrobial use among hospital inpatients in China dropped to 36% in 2019, down from 59.4% in 2011, reflecting the impact of stringent stewardship programs and regulatory measures aimed at rationalizing antibiotic prescriptions.
   
• Despite these achievements, challenges persist. High population density, regional disparities in healthcare access, and continued reliance on empirical antibiotic therapy in rural areas contribute to ongoing resistance risks. These factors create strong demand for advanced diagnostics, novel antibiotics, and infection prevention solutions.
   
• Looking ahead, China is expected to remain a dominant force in the global market, supported by robust policy frameworks, growing investments in R&D, and rapid adoption of digital health technologies.
   

Latin America Antibiotic Resistance Market

Brazil leads the Latin America market, exhibiting remarkable growth during the analysis period.
 

• Brazil is emerging as the dominant force in Latin America’s market, driven by a growing public health burden, strong government initiatives, and increasing investments in antimicrobial stewardship programs. The country’s healthcare system is prioritizing strategies to combat antimicrobial resistance (AMR), aligning with global action plans and WHO recommendations.
   
• High AMR-related mortality underscores the urgency for solutions. In 2021, Brazil recorded an estimated 31,700 deaths attributable to AMR and 130,000 deaths associated with AMR. The largest number of AMR-associated deaths occurred among individuals aged 70 years and older, highlighting the vulnerability of the aging population and the critical need for effective antibiotic therapies and infection control measures.
   
• Government-backed programs and surveillance initiatives are accelerating market growth. Brazil has strengthened its National Action Plan on AMR, expanding laboratory capacity, implementing antimicrobial stewardship in hospitals, and promoting rational antibiotic use in both human and veterinary medicine. These efforts are supported by partnerships with international organizations and increased funding for R&D of novel antibiotics and diagnostic tools.
   

Middle East and Africa Antibiotic Resistance Market

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2025.
 

• Saudi Arabia is emerging as a strategic market for antibiotic resistance solutions in the Middle East and Africa, driven by its expanding healthcare infrastructure, strong public health initiatives, and alignment with Vision 2030 goals for advanced, preventive, and technology-enabled care.
   
• The country’s healthcare transformation emphasizes infection control, antimicrobial stewardship, and rapid diagnostics, creating fertile ground for AMR-focused innovations.
   
• The growing AMR burden is a key growth driver. In 2021, Saudi Arabia recorded an estimated 2,260 deaths attributable to AMR and 8,620 deaths associated with AMR.
   
• The largest number of AMR-associated deaths occurred among individuals aged 50 to 69 years, underscoring the need for targeted interventions for middle-aged and older populations who are more vulnerable to resistant infections.
   
• With strong institutional support, rising awareness, and growing emphasis on global health security, Saudi Arabia is positioning itself as a key growth engine for the Middle East and Africa  market during the forecast period.
   

Antibiotic Resistance Market Share

The global market is shaped by a mix of established leaders and emerging innovators, creating a dynamic and rapidly evolving competitive environment. The top companies Pfizer, Merck & Co., Bayer AG, and AbbVie collectively account for 65% share of the global market, driven by their extensive antibiotic portfolios, strong R&D pipelines, and strategic collaborations across healthcare ecosystems.
 

To strengthen their market positions, leading players in the market are adopting multi‑pronged strategies, including research collaborations with academic and clinical research institutions, partnerships with government antimicrobial stewardship programs, and expansion into high‑growth regions such as Asia-Pacific. Companies are increasingly focusing on developing novel antibiotics, next‑generation antimicrobial agents, rapid diagnostics, and AI-driven drug discovery platforms to accelerate the identification of resistant pathogens and support targeted treatment selection.
 

Overall, the market is witnessing intensified competition and broader technological diversification, as both established and emerging biotechnology firms continue to innovate, scale clinical pipelines, and advance alternative therapeutic modalities to address the growing global demand for effective, high-performance solutions against antibiotic-resistant infections.
 

Antibiotic Resistance Market Companies

Prominent players operating in the antibiotic resistance industry are as mentioned below:

• AbbVie
• Basilea Pharmaceutical
• Bayer AG
• Merck and Co.
• Melinta Therapeutics
• Johnson & Johnson
• Paratek Pharmaceuticals
• Pfizer
• Shionogi & Co., Ltd.
• Tetraphase Pharmaceuticals
• Wockhardt
   

• AbbVie

AbbVie is emerging as one of the most influential players in the global antimicrobial resistance (AMR) therapeutics landscape, driven by its commitment to developing advanced antibiotic solutions for infections with limited or no current treatment options. The company’s flagship AMR product, EMBLAVEO, represents a major milestone in modern antibacterial innovation. It is a novel fixed‑dose combination therapy that pairs a monobactam (aztreonam) with a β‑lactamase inhibitor (avibactam), designed to overcome resistance mechanisms that render many existing antibiotics ineffective.
 

• Bayer AG

Bayer AG is a global leader in life sciences, specializing in healthcare and agriculture, and actively addressing critical global challenges, including antibiotic resistance. Through innovative products, strategic partnerships, and acquisitions, Bayer is making significant strides in advancing the antibiotic resistance market. The company is dedicated to sustainable solutions that improve patient care and support essential health and nutrition needs worldwide. By leveraging scientific expertise, Bayer continually develops initiatives that redefine healthcare standards, enhance patient outcomes, and strengthen global efforts against antibiotic resistance.
 

• Johnson & Johnson

Johnson & Johnson brings a diversified approach to infectious disease management, combining antibiotic development with diagnostics and preventive solutions. Its competitive strength lies in global reach, integrated healthcare solutions, and strategic investments in next-generation therapies. J&J’s focus on innovation and patient-centric strategies ensures a strong foothold in the AMR market.
 

Antibiotic Resistance Market Industry News

• In July 2024, Johnson & Johnson received full approval from both the U.S. FDA and the European Commission for SIRTURO (bedaquiline), a novel diarylquinoline antibiotic used as part of combination therapy for pulmonary multidrug‑resistant tuberculosis (MDR‑TB). This regulatory milestone transitions SIRTURO from accelerated/conditional approval to full marketing authorization, following robust Phase 3 STREAM Stage 2 data demonstrating significantly improved treatment outcomes with an all‑oral bedaquiline‑containing regimen compared with older injectable‑based therapies. This strategic advancement strengthens Johnson & Johnson’s position in the antibiotic resistance landscape.
   
• In April 2024, Basilea Pharmaceutica received U.S. FDA approval for its advanced‑generation cephalosporin antibiotic ZEVTERA (ceftobiprole medocaril), expanding its market presence across multiple high‑priority resistant infection segments. The approval covers three major indications. This FDA approval significantly strengthens Basilea’s presence in the global market by expanding its U.S. footprint.
   

The antibiotic resistance research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD million from 2022 - 2035 for the following segments:

Market, By Disease

• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Bloodstream infections
• Acute bacterial skin and skin-structure infections
• Community-acquired bacterial pneumonia
• Hospital-acquired bacterial pneumonia

Market, By Pathogen

• E. coli - Escherichia coli
• K. pneumoniae - Klebsiella pneumoniae
• P. aeruginosa - Pseudomonas aeruginosa
• S. aureus - Staphylococcus aureus
• Baumannii - Acinetobacter baumannii
• S. pneumoniae - Streptococcus pneumoniae
• H. influenzae

Market, By Drug Class

• Oxazolidinones
• Cephalosporin
• Lipoglycopeptides
• Combination therapies
• Tetracyclines
• Other drug classes

Market, By Mechanism of Action

• Cell wall synthesis inhibitors
• Protein synthesis inhibitors
• DNA synthesis inhibitors
• RNA synthesis inhibitors
• Other mechanism of actions

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE